Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

BACKGROUND: About 40% of all patients with chronic myeloid leukemia are currently old or very old. They are effectively treated with imatinib, even though underrepresented in clinical studies. Furthermore, as it happens in the general population, they often receive multiple drugs for associated chro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Iurlo, Alessandra, Nobili, Alessandro, Latagliata, Roberto, Bucelli, Cristina, Castagnetti, Fausto, Breccia, Massimo, Abruzzese, Elisabetta, Cattaneo, Daniele, Fava, Carmen, Ferrero, Dario, Gozzini, Antonella, Bonifacio, Massimiliano, Tiribelli, Mario, Pregno, Patrizia, Stagno, Fabio, Vigneri, Paolo, Annunziata, Mario, Cavazzini, Francesco, Binotto, Gianni, Mansueto, Giovanna, Russo, Sabina, Falzetti, Franca, Montefusco, Enrico, Gugliotta, Gabriele, Storti, Sergio, D'Addosio, Ada M., Scaffidi, Luigi, Cortesi, Laura, Cedrone, Michele, Rossi, Antonella Russo, Avanzini, Paolo, Mauro, Endri, Spadea, Antonio, Celesti, Francesca, Giglio, Gianfranco, Isidori, Alessandro, Crugnola, Monica, Calistri, Elisabetta, Sorà, Federica, Rege-Cambrin, Giovanna, Sica, Simona, Luciano, Luigiana, Galimberti, Sara, Orlandi, Ester M., Bocchia, Monica, Tettamanti, Mauro, Alimena, Giuliana, Saglio, Giuseppe, Rosti, Gianantonio, Mannucci, Pier Mannuccio, Cortelezzi, Agostino
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2016
Schlagworte:
Clinical Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346773/
https://ncbi.nlm.nih.gov/pubmed/27579540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11657
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge